Overall, convergence of p53 pathway dysregulation across multiple layers of the trained P-NET model identified specific vulnerabilities involving MDM4, which can be therapeutically targeted with MDM4-selective inhibition in a genomically stratified prostate cancer patient population. This evidence concerns the gene TP53 and prostate cancer.